LY-334,370

LY-334,370
	4-fluoro-N-[3-(1-metil-4-piperidinol)-1H-indol-5-il]benzamid
Drugi nazivi	LY-334,370
Identifikacija
CAS registarski broj	182563-08-2
PubChem	5311258
IUPHAR ligand	20
Jmol-3D slike	Slika 1
SMILES
	CN1CCC(c2c3cc(N([H])C(c4ccc(F)cc4)=O)ccc3n([H])c2)CC1
Svojstva
Molekulska formula	C21H22FN3O
Molarna masa	351.42 g/mol
	(šta je ovo?) (verifikuj) ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

LY-334,370 je selektivni agonist 5-HT_1F receptora^[3] koga razvija Eli Lili i kompanija za lečenje migrenske glavobolje.^[4] Lek je pokazao efikasnost u fazi II kliničkih ispitivanja,^[5] ali je dalji razvoj zaustavljen usled ustanovljene toksičnosti u životinjskim ispitivanjima.^[6]

Vidi još[uredi | uredi kod]

Lasmiditan, 5-HT_1F agonist za lečenje migrene

Literatura[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Dupuis DS, Colpaert FC, Pauwels PJ (1998). „G-protein activation at 5-HT_1A receptors by the 5-HT_1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines”. Br. J. Pharmacol. 124 (2): 283–90. DOI:10.1038/sj.bjp.0701832. PMID 9641544.
↑ Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). „Possible antimigraine mechanisms of action of the 5HT_1F receptor agonist LY-334,370”. Cephalalgia 19 (10): 851–8. DOI:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103.
↑ Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). „Selective seratonin 1F (5-HT_1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial”. Lancet 358 (9289): 1230–4. DOI:10.1016/S0140-6736(01)06347-4. PMID 11675061.
↑ Ramadan NM, Buchanan TM (2006). „New and future migraine therapy”. Pharmacol. Ther. 112 (1): 199–212. DOI:10.1016/j.pharmthera.2005.04.010. PMID 16797716.

Spoljašnje veze[uredi | uredi kod]

Portal Hemija

MeSH 4-fluoro-N-(3-(1-methyl-4-piperidinyl)-1H-indol-5-yl)benzamide

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid9641544-3] Dupuis DS, Colpaert FC, Pauwels PJ (1998). „G-protein activation at 5-HT_1A receptors by the 5-HT_1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines”. Br. J. Pharmacol. 124 (2): 283–90. DOI:10.1038/sj.bjp.0701832. PMID 9641544.

[pmid10668103-4] Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). „Possible antimigraine mechanisms of action of the 5HT_1F receptor agonist LY-334,370”. Cephalalgia 19 (10): 851–8. DOI:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103.

[pmid11675061-5] Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). „Selective seratonin 1F (5-HT_1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial”. Lancet 358 (9289): 1230–4. DOI:10.1016/S0140-6736(01)06347-4. PMID 11675061.

[pmid16797716-6] Ramadan NM, Buchanan TM (2006). „New and future migraine therapy”. Pharmacol. Ther. 112 (1): 199–212. DOI:10.1016/j.pharmthera.2005.04.010. PMID 16797716.

[1]

[2]

[3]

[4]

[5]

[6]

LY-334,370

Vidi još[uredi | uredi kod]

Literatura[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga